This is an open-label, randomized, phase II trial to test the efficacy of Ibrutinib in
combination with either Nivolumab or Cetuximab in the treatment of recurrent and/or
metastatic head an neck squamous cell carcinoma
Open-label, randomized, controlled, clinical trial. Enrollment will be stratified by HPV
status and randomized in a 1:1 ratio to either ibrutinib + cetuximab or ibrutinib + nivolumab
The study will enroll patients who develop R/M HNSCC have not yet been treated with EGFR
inhibitors in the recurrent/metastatic setting. All patients being considered for the study
must be ≥ 18 years of age and will receive: i) ibrutinib + cetuximab or ii) ibrutinib +
To determine the clinical efficacy of ibrutinib in combination with cetuximab or nivolumab in
patients with R/M HNSCC.
Ibrutinib will be supplied by Pharmacyclics as 140 mg hard gelatin capsules for oral (PO)
Cetuximab will be supplied as a clear, colorless liquid formulated for intravenous
Nivolumab will be supplied as a clear, colorless liquid formulated for intravenous
- To be enrolled in the study, each potential subject must satisfy all of the following
1. Histologically or cytologically proven squamous cell carcinoma of the head and neck
not amenable to curative intent therapy. P16 or HPV status must be known on all
patients with oropharyngeal primaries or unknown primaries.
2. Known p16 and/or HPV status by institutional standard.
3. Presence of measurable tumor lesions per RECIST criteria v1.1 by investigator review
4. Life expectancy greater than 12 weeks
5. Previously archived or newly obtained tumor specimens for correlative analysis
6. Adequate hematologic function independent of transfusion and growth factor support for
at least 7 days prior to screening and randomization, with the exception of pegylated
G-CSF (pegfilgrastim) and darbepoetin which require at least 14 days prior to
screening and randomization defined as:
- Absolute neutrophil count >750 cells/mm3 (0.75 x 109/L).
- Platelet count >50,000 cells/mm3 (50 x 109/L).
- Hemoglobin >8.0 g/dL.
7. Adequate hepatic and renal function defined as:
- Serum aspartate transaminase (AST) or alanine transaminase (ALT) ≤ 3.0 x upper
limit of normal (ULN).
- Estimated Creatinine Clearance ≥30 ml/min (Cockcroft-Gault)
- Bilirubin ≤1.5 x ULN (unless bilirubin rise is due to Gilbert's syndrome or of
8. PT/INR <1.5 x ULN and PTT (aPTT) <1.5 x ULN
9. Men and women ≥ 18 years of age.
10. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
11. Female subjects who are of non-reproductive potential (ie, post-menopausal by history
- no menses for ≥1 year; OR history of hysterectomy; OR history of bilateral tubal
ligation; OR history of bilateral oophorectomy). Female subjects of childbearing
potential must have a negative serum pregnancy test upon study entry.
12. Male and female subjects who agree to use highly effective methods of birth control
(eg, , implants, injectables, combined oral contraceptives, some intrauterine devices
[IUDs], complete abstinence, or sterilized partner) and a barrier method (eg.,
condoms, vaginal ring, sponge, etc) during the period of therapy and for for 30 days
after the last dose of study drug for females and 90 days for males.Ability and
willingness to provide written informed consent
- To be enrolled in the study, potential subjects must meet NONE of the following exclusion
1. Prior therapy with an EGFR inhibitor in the recurrent or metastatic setting
2. Nasopharyngeal carcinoma histology
3. Known, clinically active central nervous system metastases (stable metastases
4. Chemotherapy ≤ 28 days prior to first administration of study treatment and/or
monoclonal antibody (including immunotherapy) ≤16 weeks prior to first administration
of study treatment.
5. Prior exposure to BTK inhibitor, PD-1 inhibitor, or PD-L1 inhibitor
6. History of other malignancies, except:
- Malignancy treated with curative intent and with no known active disease present
for ≥3 years before the first dose of study drug and felt to be at low risk for
recurrence by treating physician.
- Adequately treated non-melanoma skin cancer or lentigo maligna without evidence
- Adequately treated carcinoma in situ without evidence of disease.
7. Concurrent systemic immunosuppressant therapy (eg, cyclosporine A, tacrolimus, etc.,
or chronic administration [>14 days] of >10 mg/day of prednisone) within 28 days of
the first dose of study drug.
8. Vaccinated with live, attenuated vaccines within 4 weeks of first dose of study drug.
9. Recent infection requiring systemic treatment that was completed ≤14 days before the
first dose of study drug.
10. Unresolved toxicities from prior anti-cancer therapy, defined as having not resolved
to Common Terminology Criteria for Adverse Event (CTCAE v4.0), Grade ≤1, or to the
levels dictated in the inclusion/exclusion criteria with the exception of alopecia.
11. Known bleeding disorders (eg, von Willebrand's disease) or hemophilia.
12. History of stroke or intracranial hemorrhage within 6 months prior to enrollment.
13. Known history of human immunodeficiency virus (HIV) or active with hepatitis C virus
(HCV) or hepatitis B virus (HBV). Subjects who are positive for hepatitis B core
antibody, hepatitis B surface antigen, or hepatitis C antibody must have a negative
polymerase chain reaction (PCR) result before enrollment. Those who are PCR positive
will be excluded.
14. Any uncontrolled active systemic infection.
15. Any history of interstitial lung disease.
16. Active autoimmune disease or other contraindication to PD-1 inhibition.
17. Major surgery within 4 weeks of first dose of study drug.
18. Any life-threatening illness, medical condition, or organ system dysfunction that, in
the investigator's opinion, could compromise the subject's safety or put the study
outcomes at undue risk.
19. Currently active, clinically significant cardiovascular disease, such as uncontrolled
arrhythmia or Class 3 or 4 congestive heart failure as defined by the New York Heart
Association Functional Classification; or a history of myocardial infarction, unstable
angina, or acute coronary syndrome within 6 months prior to randomization.
20. Unable to swallow capsules or malabsorption syndrome, disease significantly affecting
gastrointestinal function, or resection of the stomach or small bowel, symptomatic
inflammatory bowel disease or ulcerative colitis, or partial or complete bowel
21. Concomitant use of warfarin or other Vitamin K antagonists.
22. Requires treatment with a strong cytochrome P450 (CYP) 3A inhibitor
23. Currently active, clinically significant hepatic impairment Child-Pugh Class B or C
according to the Child-Pugh Classification
24. Lactating or pregnant.
25. Unwilling or unable to participate in all required study evaluations and procedures.
26. Unable to understand the purpose and risks of the study and to provide a signed and
dated informed consent form (ICF) and authorization to use protected health
information (in accordance with national and local subject privacy regulations).